Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering

CRANFORD, N.J., April 30, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commerci

PR NewswireMay 1 04:05

Citius Pharmaceuticals Announces $15 Million Registered Direct Offering

Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and...

PR NewswireApr 26 20:00

12 Health Care Stocks Moving In Thursday's Pre-Market Session

GainersBio-Path Hldgs (NASDAQ:BPTH) shares increased by 43.8% to $4.66 during Thursday's pre-market session. The market value of their outstanding shares is at $3.5 million. SINTX Techs (NASDAQ:SINT)

BenzingaApr 18 20:09

University Of Minnesota Masonic Cancer Center Intends To Expand Cirtrus Pharmaceuticals' Ongoing Investigator-Initiated Phase 1 Trial Of LYMPHIR In Combination With FDA-Approved CAR-T Products For B-cell Lymphomas

National Cancer Institute (NCI)-designated research and treatment center City of Hope, in Duarte, CA, to participate in the University of Minnesota (UMN) Masonic Cancer Center's ongoing Phase 1 trial

BenzingaApr 11 20:40

Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination With CAR-T for the Treatment of B-Cell Lymphoma

Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing...

PR NewswireApr 11 20:30

Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference

Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and...

PR NewswireApr 4 20:30